Payment overview · 2025
General Payments
$228.48
22 reported records · 4 companies
Healthcare provider profile · identity verified
David B Kimbell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALLIANCE, OH · NPI 1427057819
Verified facts
What the public records show
CMS Open Payments records show David B Kimbell, M.D. received $228.48 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 70.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.08 | 70.9% | 16 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $44.66 | 19.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.89 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.85 | 3.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.48 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.79 | 14 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $44.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.64 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.85 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1093 | 267 |
| Amlodipine Besylate | Amlodipine Besylate | 989 | 240 |
| Atorvastatin Calcium | Atorvastatin Calcium | 768 | 182 |
| Metoprolol Succinate | Metoprolol Succinate | 651 | 150 |
| Omeprazole | Omeprazole | 624 | 154 |
| Lisinopril | Lisinopril | 603 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 533 | 124 |
| Metformin Hcl | Metformin Hcl | 446 | 104 |
| Losartan Potassium | Losartan Potassium | 395 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 365 | 76 |
| Furosemide | Furosemide | 329 | 81 |
| Alprazolam | Alprazolam | 318 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 303 | 78 |
| Pregabalin | Pregabalin | 296 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 73 |
| Valsartan | Valsartan | 275 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 271 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 61 |
| Gabapentin | Gabapentin | 268 | 67 |
| Mirtazapine | Mirtazapine | 245 | 46 |
| Simvastatin | Simvastatin | 241 | 59 |
| Eliquis | Apixaban | 235 | 51 |
| Meloxicam | Meloxicam | 225 | 54 |
| Potassium Chloride | Potassium Chloride | 219 | 44 |
| Finasteride | Finasteride | 215 | 51 |
| Tramadol Hcl | Tramadol Hcl | 213 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 65 |
| Montelukast Sodium | Montelukast Sodium | 201 | 50 |
| Glimepiride | Glimepiride | 194 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 191 | 46 |
| Prednisone | Prednisone | 186 | 113 |
| Jardiance | Empagliflozin | 180 | 34 |
| Allopurinol | Allopurinol | 157 | 37 |
| Xarelto | Rivaroxaban | 154 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 153 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 146 | 126 |
| Methylprednisolone | Methylprednisolone | 146 | 109 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 143 | 35 |
| Carvedilol | Carvedilol | 140 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 140 | 108 |
| Celecoxib | Celecoxib | 137 | 35 |
| Ezetimibe | Ezetimibe | 135 | 39 |
| Famotidine | Famotidine | 131 | 37 |
| Lorazepam | Lorazepam | 126 | 34 |
| Trazodone Hcl | Trazodone Hcl | 125 | 30 |
| Irbesartan | Irbesartan | 121 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 115 | 38 |
| Metformin Hcl Er | Metformin Hcl | 113 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 30 |
| Donepezil Hcl | Donepezil Hcl | 111 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 18 |
| Ozempic | Semaglutide | 110 | 26 |
| Atenolol | Atenolol | 108 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 19 |
| Synthroid | Levothyroxine Sodium | 88 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 85 | 18 |
| Spironolactone | Spironolactone | 85 | 24 |
| Warfarin Sodium | Warfarin Sodium | 82 | 19 |
| Sertraline Hcl | Sertraline Hcl | 80 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 22 |
| Buspirone Hcl | Buspirone Hcl | 78 | 19 |
| Memantine Hcl | Memantine Hcl | 77 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 22 |
| Glipizide | Glipizide | 71 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 56 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 17 |
| Alendronate Sodium | Alendronate Sodium | 64 | 12 |
| Farxiga | Dapagliflozin Propanediol | 64 | 12 |
| Azithromycin | Azithromycin | 61 | 50 |
| Fenofibrate | Fenofibrate | 58 | 13 |
| Amoxicillin | Amoxicillin | 56 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 18 |
| Valacyclovir | Valacyclovir Hcl | 54 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Cephalexin | Cephalexin | 52 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 47 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 23 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Glipizide Er | Glipizide | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 41 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 24 |
| Colestipol Hcl | Colestipol Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 13 |
| Sotalol | Sotalol Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 12 |
| Topiramate | Topiramate | 37 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Lubiprostone | Lubiprostone | 34 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Methimazole | Methimazole | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Trimethoprim | Trimethoprim | 19 | 14 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.48 · 22 records | Novo Nordisk Inc | Leqembi, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error